Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11999773
Anti-BCMA chimeric antigen receptors
granted -
IT 202200024948
Composti attivatori dei canali potassio KV7.2/KV7.3
granted -
IT 202200024963
Composti attivatori dei canali potassio Kv7.2/Kv7.3
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
US 12005220
Microneedle patch for immunostimulatory drug delivery
granted -
US 12006517
Method for purification of bacteriophage particles
granted -
US 12006522
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
granted -
US 12006365
Human anti-semaphorin 4D antibody
granted -
US 12006516
Differentiation of pancreatic endocrine cells
granted -
US 12006329
Protein degraders and uses thereof
granted -
US 12006364
Anti-CD100 antibodies and methods for using the same
granted -
US 12006363
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
granted -
US 12006355
Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
granted -
US 12006321
Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
granted -
US 12006294
Therapeutic compounds
granted -
US 12006298
Polymorphic compounds and uses thereof
granted -
US 12005115
Epstein-barr virus vaccines
granted -
US 12005123
Conjugate of isotretinoin and peptide
granted -
US 12005126
Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption
granted -
US 12005074
Extrahepatic delivery
granted -
US 12005066
Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 12005052
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 12005060
Ophthalmic formulations of methotrexate
granted -
US 12005055
Methods for shrinking pituitary tumors
granted -
US 12005127
DNA-PK inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 12005124
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12004819
System and method of performing treatment along a lumen network
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12006348
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
granted -
US 12006341
Methods of detection and removal of rhabdoviruses from cell lines
granted -
US 12005061
Ophthalmic formulations of methotrexate
granted -
US 12005069
Bortezomib compositions
granted -
US 12005054
Piperidinyl-3-(aryloxy)propanamides and propanoates
granted -
US 12005086
Microbiome related immunotherapies
granted -
US 12005051
Topical roflumilast formulation having improved delivery and plasma half life
granted -
US 12005118
Pharmaceutical compositions comprising meloxicam
granted -
US 12005036
Methods of administering solriamfetol to lactating women
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
CA 3256311
MÉTHODES D'AMÉLIORATION DE LA SANTÉ OSSEUSE AU MOYEN DE PRODUITS ENRICHIS EN EXOSOMES DE LAIT BOVIN ET DE VITAMINE K2
granted -
US 12012459
OX40-binding polypeptides and uses thereof
granted -
US 12011390
Lacrimal drug delivery device
granted -
US 12012384
Dextrorphan prodrugs and processes for making and using them
granted -
US 12012468
Cyclic polypeptides for PCSK9 inhibition
granted -
US 12012445
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12013406
Methods of detecting anti-folic acid antibodies and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.